Cargando…
Combination of three cytotoxic agents in small-cell lung cancer
PURPOSE: The established treatment for small-cell lung cancer has been a cisplatin–etoposide combination, as the most effective chemotherapy regimen. Paclitaxel has also been used in combination with cisplatin and etoposide but this has been unacceptable due to the toxicity. This toxicity could be a...
Autores principales: | Stathopoulos, G. P., Trafalis, D., Dimitroulis, J., Kosmas, Ch., Stathopoulos, J., Tsavdaridis, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556467/ https://www.ncbi.nlm.nih.gov/pubmed/23161410 http://dx.doi.org/10.1007/s00280-012-2022-8 |
Ejemplares similares
-
Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial
por: Stathopoulos, G P, et al.
Publicado: (2005) -
Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
por: Stathopoulos, G. P., et al.
Publicado: (2011) -
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
por: Stathopoulos, G. P., et al.
Publicado: (2010) -
Immune Resistance in Lung Adenocarcinoma
por: Spella, Magda, et al.
Publicado: (2021) -
The Impact of Lower Extremity Venous Ulcers due to Chronic Venous Insufficiency on Quality of Life
por: Koupidis, Sotirios A, et al.
Publicado: (2008)